Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 8/20 | 0.78 |
| ▸ | SORT1 | Q99523 | 8/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | GAA | P10253 | 4/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | HTR1E | P28566 | 1/20 | 0.56 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069753 | 0.87 | GRN (1.00) | GRNSORT1ALDH1A1NPSR1MAPK1 | |
| SCHEMBL24283481 | 0.82 | GRN (1.00) | GRNSORT1ALDH1A1NPSR1MAPK1 | |
| SCHEMBL22000813 | 0.82 | HDAC3 (0.55) | GRNSORT1ALDH1A1NPSR1MAPK1 | |
| SCHEMBL7192267 | 0.80 | P2RY14 (0.56) | GRNSORT1ALDH1A1NPSR1MAPK1 | |
| SCHEMBL7934400 | 0.79 | P2RY14 (0.55) | GRNSORT1ALDH1A1NPSR1MAPK1 | |
| SCHEMBL1607135 | 0.78 | HDAC6 (0.58) | GRNSORT1ALDH1A1NPSR1MAPK1 | |
| SCHEMBL13219146 | 0.78 | GRN (0.82) | GRNSORT1ALDH1A1NPSR1MAPK1 | |
| SCHEMBL893061 | 0.78 | GRN (0.82) | GRNSORT1ALDH1A1NPSR1MAPK1 | |
| SCHEMBL7739178 | 0.78 | GRN (0.79) | GRNSORT1ALDH1A1NPSR1MAPK1 | |
| 4-Chloroaniline SCHEMBL7744339 | 0.78 | GRN (0.79) | GRNSORT1ALDH1A1NPSR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102659774-A | Piperidine and piperazine derivatives as P2X3 antagonists | HOFFMANN LA ROCHE | 2012-09-12 | — | — | CN | disclosed |
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| CN-101282972-A | Piperidine and piperazine derivatives as P2X3 antagonists | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | CN | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
| EP-1545523-A1 | 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS | Astex Technology Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005002673-A1 | RAF KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004004720-A1 | 3-`(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES AS P38 MAP KINASE INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | GRN 4261/4885SORT1 4830/4885ALDH1A1 2159/4885 |
| US-20060063782-A1 | 3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors | MAPK1, MAPK3, MAPK10 | GRN 2419/4885SORT1 4525/4885ALDH1A1 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.